Objective To explore the effectiveness and safety of ziprasidone in the treatment of female patients with schizophrenia.
Methods A before-after study design with prospective consecutive data collection was adopted. From June 2006 to May 2007, 30 female patients with schizophrenia discharged from the Second Veterans Hospital of Shanxi Province were included. Ziprasidone 60-120 mg/d was orally administered for 6 weeks. Positive and Negative Syndrome Scale (PANSS) and Treatment Emergent Symptom Scale (TESS) were measured before the treatment and at the end of Week 2, 4 and 6 after the treatment, respectively.
Results At Week 6, the significant improvement rate and the total improvement rate were 86.67% and 93.33%, respectively; the incidence of side effects was 86.67%.
Conclusion Ziprasidone is safe and effective in the treatment of schizophrenia. Since it will not increase body weight or the level of prolactin, it can be especially applied to female schizophrenic patients.
Citation： CHEN Jingyu,RUAN Shixiu. Effectiveness and Safety of Ziprasidone for Female Patients with Schizophrenia: A Before-after Study. Chinese Journal of Evidence-Based Medicine, 2007, 07(10): 761-764. doi: Copy